Use of fixed-dose combinations for cardiovascular indications from 2018 to 2023: a nationwide population-based study

Journal of Hypertension, Journal Year: 2024, Volume and Issue: 42(10), P. 1720 - 1727

Published: June 11, 2024

Clinical guidelines support the use of fixed-dose combinations (FDC) for prevention cardiovascular disease. Implementation FDC into clinical care remains challenging, and current population-based data are scarce.

Language: Английский

---

Lipid goal achievement one month after myocardial infarction: Observational real-world study from Polish population

Kardiologia Polska, Journal Year: 2024, Volume and Issue: 82(9), P. 892 - 894

Published: July 30, 2024

Language: Английский

---

Effect of a single pill concept on clinical and pharmacoeconomic outcomes in cardiovascular diseases

European Heart Journal - Cardiovascular Pharmacotherapy, Journal Year: 2024, Volume and Issue: unknown

Published: July 31, 2024

Abstract Aims Our study aimed to assess whether a single pill concept (SPC) is superior multi-pill (MPC) in reducing cardiovascular (CV) events, all-cause death, and costs CV patients. Method results Anonymized medical claims data covering 2012–2018, including patients with hypertension, dyslipidaemia, diseases who started drug therapy either as SPC or identical MPC were analysed after 1:1-propensity score matching. Hospitalizations predefined mortality, studied 25 311 using incidence rate ratios (IRRs) non-parametric tests for continuous variables. IRRs significantly lower SPC: stroke (IRR = 0.77; 95% CI 0.67–0.88; P < 0.001), transitory ischaemic attack 0.61; 0.48–0.78; myocardial infarction 0.76; 0.63–0.90; 0.0016), coronary artery disease 0.66; 0.57–0.77; heart failure 0.59; 0.54–0.64; acute renal 0.54; 0.56–0.64; all cause hospitalization 0.72; 0.71–0.74; 0.63; 0.57–0.69; mortality 0.62; 0.57–0.68; 0.001). Mean time first events death also favour of SPC. total 4708€ vs. 5.669€ MPC, respectively (mean ratio 0.830, Conclusion associated rates regarding pharmacoeconomic parameters should therefore become standard care improve outcomes reduce healthcare costs.

Language: Английский

---

A Nation-Wide Evaluation of Suboptimal Lipid-Lowering Treatment Patterns Among Patients Undergoing Intervention for Acute Coronary Syndrome in Hungary

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(21), P. 6562 - 6562

Published: Oct. 31, 2024

: A significant gap exists between guideline recommendations and everyday practice. Stringent treatment is needed for vulnerable patients with acute coronary syndrome (ACS).

Language: Английский

---

Ezetimibe: Integrating Established Use with New Evidence - A Comprehensive Review

Current Atherosclerosis Reports, Journal Year: 2024, Volume and Issue: 27(1)

Published: Nov. 25, 2024

Language: Английский

---